2019’s second mega-merger has emerged, and Vantage has crunched some EvaluatePharma data to help dissect the proposed deal.
The developer of Keytruda is starting to look like a one-drug company; what must it do to avoid becoming the next Abbvie?
On sales per employee Abbvie and Bristol-Myers Squibb lead the big pharma pack, while Sanofi and Astrazeneca are the sector laggards.
Orencia’s late-stage failure in Sjögren’s has dashed hopes of a therapy soon, but the mid-stage pipeline is crowded, with Novartis, Glaxosmithkline and Galapagos all…
A key update confirms ARQ 531 as the leading contender to treat patients who relapse on Imbruvica or Calquence.
Beigene seeks very good data in Waldenström's macroglobulinaemia, while Galapagos aims to extend filgotinib's reach.
After last year’s flop of Prothena’s NEOD001, Takeda’s Ninlaro fails to treat the underlying cause of the non-genetic form of this disease.